Maximising the commercial impact of (meta-)genomics via bespoke HMM and big data tools

通过定制 HMM 和大数据工具最大化（元）基因组学的商业影响

• 批准号: 132161
• 金额: $ 13.86万
• 依托单位: PROZOMIX LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132161
• 关键词: Maximising; commercial; impact; meta; genomics

This project aims to develop specialised cloud computing software at Newcastle University designed specificallyfor big data applications in the area of bioinformatics. The new software will enable scientists at ProzomixLimited to develop very large panels of biological catalysts (enzyme products) for various fields of application,but principally the production of active pharmaceutical ingredients (APIs) by synthetic chemists. Such Green-Chemistry industrial processes are in great demand as they offer the ability to produce such high valuechemicals with significantly less impact on the environment, such as from heavy metals, solvent and otherprocessing waste generated by traditional chemical processes. As a result such bioprocesses can also reducethe cost of production of APIs, leading to a positive societal impact through wider availability/increasedeffectiveness of drugs. This project will further cement the position of Prozomix Limited as a key supplier ofsuch innovative biocatalysis enzyme screening products/services, and significantly contribute to the ambition ofthe company to become the gold-standard supplier in this rapidly expanding commercial sector.

该项目旨在纽卡斯尔大学开发专门的云计算软件，专门用于生物信息学领域的大数据应用。新软件将使Prozomix Limited的科学家能够为各种应用领域开发非常大的生物催化剂（酶产品），但主要是合成化学家生产活性药物成分（API）。这种绿色化学工业工艺的需求量很大，因为它们能够生产高价值的化学品，对环境的影响明显较小，例如传统化学工艺产生的重金属，溶剂和其他加工废物。因此，这种生物工艺还可以降低原料药的生产成本，通过更广泛的药物可用性/提高药物的有效性产生积极的社会影响。该项目将进一步巩固Prozomix Limited作为此类创新生物催化酶筛选产品/服务的主要供应商的地位，并为公司成为这个快速扩张的商业领域的黄金标准供应商的雄心做出重大贡献。